Related Experiment Video
Updated: Jun 3, 2026

Th17 Inflammation Model of Oropharyngeal Candidiasis in Immunodeficient Mice
Published on: February 18, 2015
IL-22 and TNF-α represent a key cytokine combination for epidermal integrity during infection with Candida albicans
Stefanie Eyerich1, Jeanette Wagener, Vera Wenzel
1ZAUM-Center for Allergy and Environment, Technische Universität and Helmholtz Center Munich, Munich, Germany. stefanie.eyerich@lrz.tum.de
Abstract:
T cells exercise their full impact on target cells through a combination of secreted cytokines. The recently described T helper cell subset Th22 is characterized by a combinatorial secretion of IL-22 and TNF-α. Here, we demonstrate that IL-22 increases the TNF-α-dependent induction and secretion of several immune-modulatory molecules such as initial complement factors C1r and C1s, antimicrobial peptides S100A7 and HBD-2 (human β defensin 2), and antimicrobial chemokines CXCL-9/-10/-11 in primary human keratinocytes. The synergism of IL-22 and TNF-α is transmitted intracellularly by MAP kinases and downstream by transcription factors of the AP-1 family. The induction of innate immunity is relevant in an in vitro infection model, where keratinocytes stimulated with Th22 supernatants or recombinant IL-22 plus TNF-α effectively inhibit the growth of Candida albicans and maintain survival of epithelia. Accordingly, the combinatorial stimulation of keratinocytes with IL-22 and TNF-α most efficiently conserves the integrity of the epidermal barrier in a three-dimensional skin infection model as compared with IFN-γ, IL-17, IL-22 or TNF-α alone. In summary, we demonstrate that IL-22 and TNF-α represent a potent, synergistic cytokine combination for cutaneous immunity.
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Candidiasis
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Inflammatory Bowel Disease III: Crohn's Disease
Cell-mediated Immune Responses
Inflammatory Bowel Disease II: Ulcerative Colitis
